Edwards Lifesciences acquires Innovalve Bio Medical, a transcatheter mitral valve replacement company.

Edwards Lifesciences acquires Innovalve Bio Medical, an early-stage transcatheter mitral valve replacement company, exercising its option after an initial investment in 2017. Innovalve's technologies, combined with Edwards' expertise, are expected to expand treatable populations. No financial details were disclosed, but the acquisition value is estimated at hundreds of millions of dollars.